Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 133Stomach Neoplasms 111Colonic Neoplasms 101Pancreatic Neoplasms 81Neoplasm Metastasis 57Esophageal Neoplasms 48Neoplasms 31Adenocarcinoma Of Esophagus 23Adenocarcinoma 21Carcinoma, Hepatocellular 20Carcinoma, Non-Small-Cell Lung 16Biliary Tract Neoplasms 16Gallbladder Neoplasms 15Cholangiocarcinoma 15Gastrointestinal Neoplasms 14Liver Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Unspecified Adult Solid Tumor, Protocol Specific 11Esophageal Squamous Cell Carcinoma 11Bile Duct Neoplasms 10Recurrence 9Peritoneal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Appendiceal Neoplasms 5Advanced Gastric Cancer 5

Interventions

mogamulizumab 4Lenalidomide 3Cyclophosphamide 3Alemtuzumab 2peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cobomarsen 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia-Lymphoma, Adult T-Cell × Oxaliplatin × Clear all
NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
71 enrolled 15 charts
LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡